Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

Abstract Background Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA®; OTX-101), cyclosporine ophthalmic emulsion 0.05% (Restas...

Full description

Bibliographic Details
Main Authors: Paul Karpecki, Victoria Barghout, Brad Schenkel, Lynn Huynh, Anamika Khanal, Brittany Mitchell, Mihran Yenikomshian, Enrico Zanardo, Cynthia Matossian
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Ophthalmology
Subjects:
Cyclosporine A
Discontinuation
Keratoconjunctivitis sicca
Persistence
Online Access:https://doi.org/10.1186/s12886-023-03174-y

Internet

https://doi.org/10.1186/s12886-023-03174-y

Similar Items